XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (XOMAO)
XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (XOMAO) represents a preferred equity security issued by XOMA Royalty Corporation. It offers investors a fixed cumulative dividend rate of 8.375%, payable annually, and typically has priority over common stock in dividend payments and asset distribution. The shares are often structured as depositary receipts, allowing investors to hold fractional interests in the preferred stock.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 15, 2025 | $0.52 | 2025-10-03 | 2025-10-03 |
| July 15, 2025 | $0.52 | 2025-07-03 | 2025-07-03 |
| April 15, 2025 | $0.52 | 2025-04-03 | 2025-04-03 |
| January 15, 2025 | $0.52 | 2025-01-03 | 2025-01-03 |
| October 15, 2024 | $0.52 | 2024-10-03 | 2024-10-03 |
Dividends Summary
- XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock has issued 18 dividend payments over the past 4 years
- The most recent dividend was paid 9 days ago, on October 15, 2025
- The highest dividend payed out to investors during this period was $0.56 per share
- The average dividend paid during this period was $0.53 per share.
Company News
XOMA Royalty and LAVA Therapeutics amended their share purchase agreement, reducing the initial cash amount per share to $1.04 and introducing a contingent value right (CVR). The tender offer has been extended to November 12, 2025, with the acquisition expected to close in Q4 2025.
XOMA Royalty Corporation has extended its tender offer to purchase LAVA Therapeutics shares until October 17, 2025, with a cash payment and contingent value right per share. The proposed acquisition is expected to close in Q4 2025, subject to customary closing conditions.
XOMA Corporation, a biotechnology company, announced that it will change its name to XOMA Royalty Corporation, effective July 10, 2024. The rebranding reflects the company's focus on pharmaceutical royalties.
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs.